All In Biotech

Drug Trial Radar · NCT07037433

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 12,800 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

12,800

Planned (sponsor's estimate)

Start

Jul 25, 2025

Primary completion

Jun 30, 2028

Study completion Sep 29, 2030

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Jun 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

Conditions

  • Atherosclerotic Cardiovascular Disease
  • Overweight
  • Obesity

Interventions

  • Maridebart CafraglutideDrug

    Maridebart cafraglutide will be administered SC.

  • PlaceboDrug

    Placebo will be administered SC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Occurrence of a Composite Endpoint Consisting of: CV Death, Myocardial Infarction (MI), or Ischemic Stroke (3-point Major Adverse Cardiac Events [3-P MACE])Time frame: Up to approximately 35 months
  2. Time to First Occurrence of a Composite Endpoint Consisting of: All-cause Death, MI, Ischemic Stroke, Coronary Revascularization, or Heart Failure (HF) Event (5-point MACE)Time frame: Up to approximately 35 months

Locations

783 sites in 36 countries. Site status is shown where the registry gives one.

  • Alliance For Multispecialty Research - Daphne

    Daphne, Alabama

  • Eastern Shore Research Institute

    Fairhope, Alabama

  • Huntsville Clinical Research, LLC

    Huntsville, Alabama

  • Mobile Heart Specialists PC

    Mobile, Alabama

  • Syed Research Consultants LLC

    Sheffield, Alabama

  • Synexus Clinical Research US, Inc.

    Phoenix, Arizona

  • Medical Advancement Centers of Arizona

    Phoenix, Arizona

  • Valley Clinical Trials, LLC dba Flourish Research

    Covina, California

  • Velocity Clinical Research- Huntington Park

    Huntington Park, California

  • Velocity Clinical Research- Los Angeles

    La Mesa, California

  • Orange County Research Center

    Lake Forest, California

  • Biopharma Informatic - The Cardiovascular Center

    Redding, California

  • Acclaim Clinical Research

    San Diego, California

  • Encompass Clinical Research

    Spring Valley, California

  • Diablo Clinical Research

    Walnut Creek, California

  • Focus Clinical Research

    West Hills, California

  • Family Practice Associates

    Wilmington, Delaware

  • Excel Medical Clinical Trials

    Boca Raton, Florida

  • Velocity Clinical Research - New Smyrna Beach

    Edgewater, Florida

  • Alliance for Multispecialty Research - Fort Myers

    Fort Myers, Florida

  • Elite Cardiac Research Center LLC

    Hialeah, Florida

  • Elite Clinical Research

    Hialeah, Florida

  • Zenith Clinical Research

    Hollywood, Florida

  • Encore Medical Research LLC

    Hollywood, Florida

  • East Coast Institute for Research, LLC

    Jacksonville, Florida

  • Clinical Research of Central Florida

    Lakeland, Florida

  • South Florida Clinical Research

    Margate, Florida

  • Finlay Medical Research

    Miami, Florida

  • Suncoast Research Group LLC

    Miami, Florida

  • New Horizon Research Center

    Miami, Florida

  • Panax Clinical Research

    Miami Lakes, Florida

  • San Marcus Research Clinic Inc

    Miami Lakes, Florida

  • Indago Research and Health Center

    Miami Lakes, Florida

  • West Orange Endocrinology

    Ocoee, Florida

  • Cardiology Partners Clinical Research Institute

    Palm Beach Gardens, Florida

  • Peace River Cardiovascular Center

    Port Charlotte, Florida

  • Progressive Medical Research

    Port Orange, Florida

  • Saint Johns Center for Clinical Research

    Saint Augustine, Florida

  • Intercoastal Medical Group

    Sarasota, Florida

  • Winter Haven Hospital

    Winter Haven, Florida

Showing 40 of 783 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.